Literature DB >> 28153789

Oncogenic signaling of MEK5-ERK5.

Van T Hoang1, Thomas J Yan1, Jane E Cavanaugh2, Patrick T Flaherty2, Barbara S Beckman3, Matthew E Burow4.   

Abstract

Mitogen-activated protein kinases (MAPKs) regulate diverse cellular processes including proliferation, cell survival, differentiation, and apoptosis. While conventional MAPK constituents have well-defined roles in oncogenesis, the MEK5 pathway has only recently emerged in cancer research. In this review, we consider the MEK5 signaling cascade, focusing specifically on its involvement in drug resistance and regulation of aggressive cancer phenotypes. Moreover, we explore the role of MEK5/ERK5 in tumorigenesis and metastatic progression, discussing the discrepancies in preclinical studies and assessing its viability as a therapeutic target for anti-cancer agents.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cellular signaling; Kinase inhibitors; MEK5-ERK5; Mitogen-activated protein kinase; Targeted therapies

Mesh：

Substances：

Year:  2017        PMID： 28153789      PMCID： PMC5901897          DOI： 10.1016/j.canlet.2017.01.034

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  97 in total

Review 1.  Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.

Authors:  Nicola Normanno; Massimo Di Maio; Ermelinda De Maio; Antonella De Luca; Andrea de Matteis; Antonio Giordano; Francesco Perrone
Journal:  Endocr Relat Cancer       Date:  2005-12       Impact factor: 5.678

Review 2.  Matrix metalloproteinases and tumor metastasis.

Authors:  Elena I Deryugina; James P Quigley
Journal:  Cancer Metastasis Rev       Date:  2006-03       Impact factor: 9.264

3.  Cdc42 negatively regulates intrinsic migration of highly aggressive breast cancer cells.

Authors:  Yufeng Zuo; Yuexiu Wu; Chandan Chakraborty
Journal:  J Cell Physiol       Date:  2012-04       Impact factor: 6.384

4.  MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments.

Authors:  Mariska Miranda; Esdy Rozali; Kum Kum Khanna; Fares Al-Ejeh
Journal:  Oncoscience       Date:  2015-02-20

5.  Upregulation of MEK5 by Stat3 promotes breast cancer cell invasion and metastasis.

Authors:  Fang Liu; Hao Zhang; Hui Song
Journal:  Oncol Rep       Date:  2016-11-18       Impact factor: 3.906

6.  The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma.

Authors:  Elisabetta Rovida; Giovanni Di Maira; Ignazia Tusa; Stefania Cannito; Claudia Paternostro; Nadia Navari; Elisa Vivoli; Xianming Deng; Nathanael S Gray; Azucena Esparís-Ogando; Ezio David; Atanasio Pandiella; Persio Dello Sbarba; Maurizio Parola; Fabio Marra
Journal:  Gut       Date:  2014-09-02       Impact factor: 23.059

7.  The essential role of MEKK3 in TNF-induced NF-kappaB activation.

Authors:  J Yang; Y Lin; Z Guo; J Cheng; J Huang; L Deng; W Liao; Z Chen; Z Liu; B Su
Journal:  Nat Immunol       Date:  2001-07       Impact factor: 25.606

8.  Potent antimyeloma activity of a novel ERK5/CDK inhibitor.

Authors:  Stela Álvarez-Fernández; María Jesús Ortiz-Ruiz; Tracy Parrott; Sara Zaknoen; Enrique M Ocio; Jesús San Miguel; Francis J Burrows; Azucena Esparís-Ogando; Atanasio Pandiella
Journal:  Clin Cancer Res       Date:  2013-03-26       Impact factor: 12.531

9.  Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray.

Authors:  Christopher B Weldon; Ali B Scandurro; Kevin W Rolfe; John L Clayton; Steven Elliott; Nancy N Butler; Lilia I Melnik; Jawed Alam; John A McLachlan; Bernard M Jaffe; Barbara S Beckman; Matthew E Burow
Journal:  Surgery       Date:  2002-08       Impact factor: 3.982

10.  A novel mitogen-activated protein kinase docking site in the N terminus of MEK5alpha organizes the components of the extracellular signal-regulated kinase 5 signaling pathway.

Authors:  Jan Seyfried; Xin Wang; Giorgi Kharebava; Cathy Tournier
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272
View more
  30 in total

1.  The protein kinase MAP3K19 phosphorylates MAP2Ks and thereby activates ERK and JNK kinases and increases viability of KRAS-mutant lung cancer cells.

Authors:  Van T Hoang; Katherine Nyswaner; Pedro Torres-Ayuso; John Brognard
Journal:  J Biol Chem       Date:  2020-04-30       Impact factor: 5.157

2.  Discovery and characterization of an iminocoumarin scaffold as an inhibitor of MEKK2 (MAP3K2).

Authors:  Syed Ahmad; Valentine R St Hilaire; Srinivasa R Dandepally; Gary L Johnson; Alfred L Williams; John E Scott
Journal:  Biochem Biophys Res Commun       Date:  2018-01-05       Impact factor: 3.575

3.  KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism.

Authors:  Angelina V Vaseva; Devon R Blake; Thomas S K Gilbert; Serina Ng; Galen Hostetter; Salma H Azam; Irem Ozkan-Dagliyan; Prson Gautam; Kirsten L Bryant; Kenneth H Pearce; Laura E Herring; Haiyong Han; Lee M Graves; Agnieszka K Witkiewicz; Erik S Knudsen; Chad V Pecot; Naim Rashid; Peter J Houghton; Krister Wennerberg; Adrienne D Cox; Channing J Der
Journal:  Cancer Cell       Date:  2018-11-12       Impact factor: 31.743

4.  Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.

Authors:  Thomas D Wright; Christopher Raybuck; Akshita Bhatt; Darlene Monlish; Suravi Chakrabarty; Katy Wendekier; Nathan Gartland; Mohit Gupta; Matthew E Burow; Patrick T Flaherty; Jane E Cavanaugh
Journal:  J Cell Biochem       Date:  2019-08-28       Impact factor: 4.429

Review 5.  Kinase inhibitors: the road ahead.

Authors:  Fleur M Ferguson; Nathanael S Gray
Journal:  Nat Rev Drug Discov       Date:  2018-03-16       Impact factor: 84.694

6.  BAY-885, a mitogen-activated protein kinase kinase 5 inhibitor, induces apoptosis by regulating the endoplasmic reticulum stress/Mcl-1/Bim pathway in breast cancer cells.

Authors:  Lei Wang; Xiaochun Ji; Chenxiao Mao; Rui Yu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

7.  Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor.

Authors:  Duncan C Miller; Tristan Reuillon; Lauren Molyneux; Timothy Blackburn; Simon J Cook; Noel Edwards; Jane A Endicott; Bernard T Golding; Roger J Griffin; Ian Hardcastle; Suzannah J Harnor; Amy Heptinstall; Pamela Lochhead; Mathew P Martin; Nick C Martin; Stephanie Myers; David R Newell; Richard A Noble; Nicole Phillips; Laurent Rigoreau; Huw Thomas; Julie A Tucker; Lan-Zhen Wang; Michael J Waring; Ai-Ching Wong; Stephen R Wedge; Martin E M Noble; Celine Cano
Journal:  J Med Chem       Date:  2022-04-25       Impact factor: 8.039

Review 8.  MAPK and PI3K signaling: At the crossroads of neural crest development.

Authors:  Colin J Dinsmore; Philippe Soriano
Journal:  Dev Biol       Date:  2018-02-14       Impact factor: 3.582

9.  The MEK5-ERK5 Kinase Axis Controls Lipid Metabolism in Small-Cell Lung Cancer.

Authors:  Sandra Cristea; Garry L Coles; Daniel Hornburg; Maya Gershkovitz; Julia Arand; Siqi Cao; Triparna Sen; Stuart C Williamson; Jun W Kim; Alexandros P Drainas; Andrew He; Laurent Le Cam; Lauren Averett Byers; Michael P Snyder; Kévin Contrepois; Julien Sage
Journal:  Cancer Res       Date:  2020-01-22       Impact factor: 12.701

10.  Extracellular signal regulated kinase 5 and inflammasome in progression of mesothelioma.

Authors:  Joyce K Thompson; Anurag Shukla; Alan L Leggett; Phillip B Munson; Jill M Miller; Maximilian B MacPherson; Stacie L Beuschel; Harvey I Pass; Arti Shukla
Journal:  Oncotarget       Date:  2017-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.